Information on TNFSF12

Basic details

Alt. symbols: TWEAK | DR3LG | APO3L

Approved name: TNF superfamily member 12
Alt. names: tumor necrosis factor (ligand) superfamily, member 12

Location: 17p13.1: 7548508 - 7557890 (+)
Gene type: protein_coding, 20 transcripts.

Scores: LoFtool: 0.174000 | pLI: 0.99795402 | LOEUF: 0.408

HGNC: 11927

NCBI: 8742, RefSeq: NG_052944.1

Ensembl: ENSG00000239697.12

LRG_1320 | Status: public

OMIM: 602695

Expression | ProteinAtlas

Normal function

TNFSF12 encodes TWEAK, a ligand whose exact functions remain unclear but may work in complex with related ligands to promote apoptosis during B-cell development and selection (PMID: 9405449). Like other TNFSF ligands, TWEAK can function as a secreted or transmembrane protein (PMID: 20385556) and is widely expressed across many tissues and cell types, including monocytes/macrophages, DCs, NK cells, and T cells. It is upregulated in inflammation, and has been shown to negatively regulate innate immune activation of adaptive Th1 immunity through its receptor (PMID: 16325585).

Dysfunction and disease

By screening PAD patients with a custom 148 gene-based resequencing chip, Wang et al. (2013) identified a rare heterozygous missense mutation in a patient with impaired antibody responses, reduced IgM and IgA levels, and expanded TCRα/β+ double negative T cells (PMID: 23493554). The authors showed that this mutation did not affect TWEAK binding to its receptor (if anything slightly increased), but did impair its ability to induce apoptosis via reduced activation of NF-κB and mitog en-activated protein kinase (MAPK) pathways. Further, mutant TWEAK also showed stronger binding to BAFF, but not BAFF-R, and was found to impair downstream BAFF signaling, presumably via a DN effect such as the formation of ineffective ligand complexes. However, given some of the clinical differences between BAFF-R-deficient patients and the TWEAK patient, as well as the significant crosstalk and interactions across multiple TNFSF receptors, it is likely that altered interactions with other ligands or receptors, such as APRIL or TACI, may also contribute to the latter’s phenotype. [Load More]

[Reviewed by Xiao P. Peng on 2022-07-08 22:35:46]

Associated conditions

Acronym Condition's_name MOI Mode_of_actionwww icon OMIM_ID No.cases
CVID9 Immunodeficiency, common variable, 9 ADdict. icon - 0 (0 fams)

Please mind that full curation (inclusion of all published patients) of this gene has not started yet. Please contact us if you want to volunteer.

Transcripts of TNFSF12

Name ENSEMBL_ID LRG_ID CCDS_ID MANE Transcript.type Exons Canonical CDS_length REFSEQ_ID
201 ENST00000293825.11 1 CCDS11109 Select protein_coding 7 Yes 1377 NM_003809

Published variants

Found 0 variants

Var.name Exon/Intron cDNA_pos. CDS_change Prot.change Var.type Var.class. Patients

Please mind that full curation (inclusion of all published variants) of this gene has not started yet. Please contact us if you want to volunteer.

Diagnostic pitfalls & paradigms

Considerations to take into account when analyzing this gene

Year Paradigm ⓘ PMID Notes
- Regions of Homology -
-Cryptic splicing-Unreported or not recorded in our DB.
-Uniparental disomy-Unreported or not recorded in our DB.
-Mosaicism-Unreported or not recorded in our DB.
-Incomplete penetrance-Unreported or not recorded in our DB.
-Di-/oligo-genic inheritance-Unreported or not recorded in our DB.
-Somatic reversion-Unreported or not recorded in our DB.

References linked to variants in TNFSF12

ID Year Title Journal PMID Variants
680 2020 APRIL-dependent lifelong plasmacyte maintenance and immunogl... JACI 32298700 1

Phenotypic & functional assays available?

Find laboratories offering tests

Check